JP5731372B2 - 癌治療用腫瘍低酸素の誘発 - Google Patents

癌治療用腫瘍低酸素の誘発 Download PDF

Info

Publication number
JP5731372B2
JP5731372B2 JP2011504152A JP2011504152A JP5731372B2 JP 5731372 B2 JP5731372 B2 JP 5731372B2 JP 2011504152 A JP2011504152 A JP 2011504152A JP 2011504152 A JP2011504152 A JP 2011504152A JP 5731372 B2 JP5731372 B2 JP 5731372B2
Authority
JP
Japan
Prior art keywords
tumor
stilbene
tirapazamine
hypoxia
vda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011504152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516565A (ja
JP2011516565A5 (https=
Inventor
リー，リュイ−ミン
リン，ペク−スン
Original Assignee
ヴァージニア コモンウェルス ユニバーシティ
ヴァージニア コモンウェルス ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァージニア コモンウェルス ユニバーシティ, ヴァージニア コモンウェルス ユニバーシティ filed Critical ヴァージニア コモンウェルス ユニバーシティ
Publication of JP2011516565A publication Critical patent/JP2011516565A/ja
Publication of JP2011516565A5 publication Critical patent/JP2011516565A5/ja
Application granted granted Critical
Publication of JP5731372B2 publication Critical patent/JP5731372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011504152A 2008-04-10 2009-04-08 癌治療用腫瘍低酸素の誘発 Active JP5731372B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4396408P 2008-04-10 2008-04-10
US61/043,964 2008-04-10
PCT/US2009/039899 WO2009126705A2 (en) 2008-04-10 2009-04-08 Induction of tumor hypoxia for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015001834A Division JP5944018B2 (ja) 2008-04-10 2015-01-07 癌治療用腫瘍低酸素の誘発

Publications (3)

Publication Number Publication Date
JP2011516565A JP2011516565A (ja) 2011-05-26
JP2011516565A5 JP2011516565A5 (https=) 2012-04-05
JP5731372B2 true JP5731372B2 (ja) 2015-06-10

Family

ID=41162569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011504152A Active JP5731372B2 (ja) 2008-04-10 2009-04-08 癌治療用腫瘍低酸素の誘発
JP2015001834A Active JP5944018B2 (ja) 2008-04-10 2015-01-07 癌治療用腫瘍低酸素の誘発

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015001834A Active JP5944018B2 (ja) 2008-04-10 2015-01-07 癌治療用腫瘍低酸素の誘発

Country Status (6)

Country Link
US (4) US8591921B2 (https=)
JP (2) JP5731372B2 (https=)
KR (1) KR101925436B1 (https=)
CN (2) CN102026634B (https=)
TW (1) TWI504391B (https=)
WO (1) WO2009126705A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
US9402820B2 (en) 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
WO2013096687A1 (en) 2011-12-22 2013-06-27 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
CN102512692B (zh) * 2012-01-16 2014-07-16 北京大学 肿瘤靶向栓塞治疗组合物及其制备方法
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CA2930001A1 (en) * 2013-11-11 2015-05-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US9586056B2 (en) * 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
WO2016123313A1 (en) 2015-01-29 2016-08-04 Oxyrase, Inc. Methods for inhibiting tumor growth
EP3294313A4 (en) * 2015-05-15 2019-04-17 The General Hospital Corporation METHODS RELATING TO THE PREVENTION AND TREATMENT OF DRUG RESISTANCE
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
KR20180086195A (ko) * 2015-10-21 2018-07-30 테크리슨 리미티드 면역 매개 암 치료를 위한 조성물 및 방법
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
CN108348463A (zh) * 2016-05-13 2018-07-31 泰克利森有限公司 用于治疗肝脏组织的方法
CN107007571B (zh) * 2017-02-24 2020-08-21 福州市传染病医院 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用
CN110051848A (zh) * 2019-05-06 2019-07-26 中国科学院长春应用化学研究所 药物组合、应用以及抗肿瘤的药物
CN110585214A (zh) * 2019-09-25 2019-12-20 湖北大学 一种促进治疗肿瘤效果的纳米粒子及其合成方法
CN110713596B (zh) * 2019-11-08 2022-04-29 西北师范大学 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统
JP7730130B2 (ja) * 2021-03-02 2025-08-27 ドリームメディカルパートナーズ株式会社 塞栓材及びその製造方法
WO2023049207A1 (en) * 2021-09-22 2023-03-30 The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN114344482B (zh) * 2022-01-14 2023-05-12 重庆医科大学附属第二医院 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用
WO2024006901A1 (en) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Uses of bipolar trans carotenoids in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5624925A (en) 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
EP1155689B1 (en) 1993-07-19 2006-09-20 Angiotech Pharmaceuticals, Inc. Anti-angiogenic stents and methods of their preparation
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9404400D0 (en) 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
CA2281807C (en) 1997-03-07 2007-10-16 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CN1555253A (zh) 2001-09-13 2004-12-15 ������ѧ�����о�Ժ 化疗栓塞用紫杉醇的油性组合物、制剂及它们的制造方法
WO2004064734A2 (en) * 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Combination therapies for the treatment of cancer
US20060264388A1 (en) 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
CN102026634B (zh) 2008-04-10 2014-01-22 弗吉尼亚州立邦联大学 诱导肿瘤缺氧以治疗癌症

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ

Also Published As

Publication number Publication date
US20140065139A1 (en) 2014-03-06
JP5944018B2 (ja) 2016-07-05
US20120087913A1 (en) 2012-04-12
JP2011516565A (ja) 2011-05-26
US9649316B2 (en) 2017-05-16
WO2009126705A8 (en) 2011-04-14
CN104043125A (zh) 2014-09-17
US10426779B2 (en) 2019-10-01
CN102026634A (zh) 2011-04-20
KR20110050583A (ko) 2011-05-16
CN102026634B (zh) 2014-01-22
KR101925436B1 (ko) 2018-12-05
US10159676B2 (en) 2018-12-25
JP2015110602A (ja) 2015-06-18
WO2009126705A3 (en) 2010-02-18
TWI504391B (zh) 2015-10-21
US20180050039A1 (en) 2018-02-22
TW201002312A (en) 2010-01-16
US20170224693A1 (en) 2017-08-10
US8591921B2 (en) 2013-11-26
CN104043125B (zh) 2018-01-12
HK1202057A1 (en) 2015-09-18
WO2009126705A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
JP5944018B2 (ja) 癌治療用腫瘍低酸素の誘発
Zhao et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy
Miller et al. Poly (ethylene glycol)–paclitaxel–alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases
Kotagiri et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer
Huang et al. Photodynamic therapy synergizes with irinotecan to overcome compensatory mechanisms and improve treatment outcomes in pancreatic cancer
US10278954B2 (en) Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor
Pinkiewicz et al. A systematic review on intra-arterial cerebral infusions of chemotherapeutics in the treatment of glioblastoma multiforme: The state-of-the-art
Wang et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer
Rosenberg et al. Radiation sensitization with redox modulators: a promising approach
Cohen et al. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo
Shulman et al. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
Garona et al. Addition of vasopressin synthetic analogue [V4Q5] dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
Shen et al. Dual asparagine-depriving nanoparticles against solid tumors
William Jr et al. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer
Brem Angiogenesis antagonists: current clinical trials
HK1202057B (en) Induction of tumor hypoxia for cancer therapy
Waters et al. New Approaches to the Treatment of Gastro-lntestinal Cancer
Pilat et al. Vascular targeting agents
Liu et al. A rat toxicological study of intra-arterial injection of Tirapazamine, a hypoxia-activating Cancer therapeutic agent, followed by hepatic artery ligation
Chen et al. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer
Petronek et al. Manipulating redox active metal metabolism to enhance cancer therapy
JP2004521929A (ja) イソクマリン誘導体を使用する腫瘍の放射線増感および／または化学相乗作用
Horsman et al. 17 THE OXYGEN EFFECT AND APPROACHES TO TUMOR HYPOXIA
JP2015091766A (ja) 癌治療支援システム
Jin et al. Radiosensitization by the Combination of SR-2508 and Paclitaxel in Hypoxic Human Tumor Cells in vitro

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140303

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150127

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150409

R150 Certificate of patent or registration of utility model

Ref document number: 5731372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250